In a leaked ab­stract, J&J's cell ther­a­py ap­pears to have dra­mat­ic ben­e­fits for mul­ti­ple myelo­ma pa­tients

Pa­tients tak­ing Leg­end Biotech and John­son & John­son’s can­cer cell ther­a­py Carvyk­ti had a 74% re­duc­tion in the risk of mul­ti­ple myelo­ma pro­gres­sion or death, ac­cord­ing to a leaked ab­stract from an up­com­ing med­ical meet­ing.

The da­ta, which emerged Tues­day night and have since been tak­en down, could put Carvyk­ti ahead of com­peti­tor Abec­ma, a CAR-T de­vel­oped by Bris­tol My­ers Squibb and 2sev­en­ty bio, in ear­li­er lines of treat­ment if and when it’s ap­proved for those in­di­ca­tions. The study’s re­sults sur­prised an­a­lysts, with a Cowen an­a­lyst de­scrib­ing it as “game-chang­ing ef­fi­ca­cy,” and sent Leg­end’s shares $LEGN 14% high­er af­ter Wednes­day’s open­ing bell.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.